139 results on '"Birkett, Ashley"'
Search Results
2. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults
3. Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies
4. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study
5. The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule
6. Status of vaccine research and development of vaccines for malaria
7. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
8. Building an effective malaria vaccine pipeline to address global needs
9. Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial
10. Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody TB31F: An Open-Label, First-in-Human, Trial in Healthy Malaria-Naïve Adults
11. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
12. Interferon-α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy
13. Improved design and intranasal delivery of an M2e-based human influenza A vaccine
14. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection
15. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization againstPlasmodium falciparummalaria
16. PATH Malaria Vaccine Initiative (MVI):: Perspectives on the status of malaria vaccine development
17. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques
18. Referee report. For: Progress and challenges in TB vaccine development [version 1; referees: 2 approved]
19. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers
20. Expression of full-length Plasmodium falciparum P48/45 in P. berghei blood stages: A method to express and evaluate vaccine antigens
21. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria.
22. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.
23. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
24. Vaccines to Accelerate Malaria Elimination and Eventual Eradication
25. Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward
26. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
27. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy
28. Demonstration of the Blood-StagePlasmodium falciparumControlled Human Malaria Infection Model to Assess Efficacy of theP. falciparumApical Membrane Antigen 1 Vaccine, FMP2.1/AS01
29. A comparison of Plasmodium falciparum circumsporozoite protein-based slot blot and ELISA immuno-assays for oocyst detection in mosquito homogenates
30. Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
31. A Slot Blot Immunoassay for Quantitative Detection of Plasmodium falciparum Circumsporozoite Protein in Mosquito Midgut Oocyst
32. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
33. Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities
34. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
35. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies
36. Aligning new interventions with developing country health systems: Target product profiles, presentation, and clinical trial design
37. Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium falciparum Gametocyte Carriers
38. Producing A Successful Malaria Vaccine: Innovation In The Lab And Beyond
39. Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection
40. Expression, Purification and Characterization of Hepatitis C Virus Core Protein from E.Coli Using a Chemically Synthesized Gene (1), and Cloning, Expression, Purification and Characterization of the Major Core Protein (P26) from Equine Infectious Anaemia Virus
41. M2e-based universal influenza A vaccine
42. Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge
43. Universal influenza A vaccine: Optimization of M2-based constructs
44. Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial
45. Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes
46. Antibodies against Thrombospondin-Related Anonymous Protein Do Not Inhibit Plasmodium Sporozoite Infectivity In Vivo
47. Limited humoral immunity in hepatitis C virus infection
48. Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein
49. Cloning, expression, purification, and characterization of the major core protein (p26) from equine infectious anemia virus
50. Determination of enzyme specificity in a complex mixture of peptide substrates by N-terminal sequence analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.